Lymphoma/Leukemia (CLL/SLL): A Study Comparing BGB-3111 With Bendamustine Plus Rituximab
in Patients With Previously Untreated CLL or SLL
What are the good and bad effects of the experimental drug BGB-3111, versus a known
standard treatment called bendamustine plus rituximab (B+R) on you and your chronic
lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)?
Basic Study Information
Purpose:Location: Cancer Center
If you decide to participate in this study; as part of the screening tests for the
study, your blood will be tested to determine whether you have CLL/SLL that has a
mutation (a change) in one of the chromosomes called ‘17p deletion’.
If you have CLL/SLL that does not have the 17p deletion, you will be in Cohort 1 and
will be randomly assigned by a computer program to one of the following treatment
groups in Cohort 1: BGB-3111 or B+R. When you are “randomly assigned” it means you
are put into a group by chance, like flipping a coin. Neither you nor your study
doctor may choose the treatment you will take. You will have an equal chance of receiving
either treatment in Cohort 1.
If your CLL/SLL has the 17p deletion, you will be assigned to Cohort 2 and will receive
Study Web URL: https://clinicaltrials.gov/ct2/show/NCT03336333?term=BGB-3111-304&rank=1
Study Reference #: ILYM17110
Lead Researcher (Principal Investigator)
Lead Researcher: Paul Barr
Study Contact InformationStudy Coordinator: Delaney Dretto
Phone: (585) 275-5825
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search